Sarepta siRNA Data Fuels Share Rally
Sarepta siRNA data showed dose-dependent muscle exposure and tolerability and drove a share jump; Arrowhead licensing included a $200 million milestone.
KEY TAKEAWAYS
- Phase 1/2 readouts showed dose-dependent muscle exposure and proof-of-concept biomarker knockdown.
- Alpha v beta 6 integrin ligand delivered high muscle concentrations with no uptake saturation observed.
- Arrowhead licensing included a $200 million milestone and Sarepta provided no forward guidance.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Sarepta Therapeutics released interim Phase 1/2 data on March 25, 2026, for its siRNA programs SRP-1001 (FSHD1) and SRP-1003 (DM1), showing dose-dependent muscle exposure, biomarker knockdown, and favorable tolerability. Shares rose about 20% in early trading.
Dose-Dependent Clinical Results
The company reported Phase 1/2 results from single- and multiple-ascending-dose randomized, placebo-controlled studies enrolling patients aged 16 to 70. The data showed proof-of-concept biomarker knockdown after a single dose for both programs—DUX4 in FSHD1 and DMPK mRNA in DM1—alongside standard safety and pharmacokinetic measures.
Sarepta’s proprietary αvβ6 integrin delivery chemistry achieved high muscle tissue concentrations. Nonclinical and clinical data demonstrated consistent, dose-dependent increases in plasma and muscle exposure without saturation of muscle uptake. The company said this muscle-targeting approach could allow higher dosing and potentially translate into clinical benefit if confirmed in later-stage studies.
Safety results were broadly favorable. Most adverse events were mild to moderate and not dose-dependent, with no dose-limiting toxicity observed across tested dose levels. Sarepta highlighted tolerability as an encouraging aspect of the early program readouts.
FSHD1 affects about 16,000 diagnosed individuals in the U.S. It is a progressive disorder linked to abnormal activation of the DUX4 gene on chromosome 4 and currently has no approved disease-modifying treatment. DM1, the most common adult-onset muscular dystrophy, affects roughly 40,000 diagnosed people in the U.S. It is a multisystem disorder caused by a repeat expansion in the DMPK gene and also lacks approved disease-modifying therapies.
Licensing and Regulatory Outlook
Both siRNA programs are licensed exclusively from Arrowhead Pharmaceuticals under a prior agreement. Sarepta received a $200 million milestone payment tied to the DM1 program as part of the deal. This arrangement transfers development rights for the αvβ6 integrin-targeted programs to Sarepta while linking near-term economics to clinical progress.
The release and webcast focused on interim safety, pharmacokinetic, and pharmacodynamic data. Sarepta did not provide forward guidance but said it will monitor additional data and regulatory updates as the studies continue. No regulatory approvals or submissions for the siRNA programs were disclosed; both remain investigational in ongoing Phase 1/2 studies.
Separately, Sarepta published a regulatory update on two Duchenne muscular dystrophy products seeking an FDA meeting to discuss converting accelerated approval to standard approval. The company said this matter is distinct from the siRNA pipeline.
